Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 21, 2017. The document serves as a transaction notification regarding a Person Closely Associated (PCA) with a Principal Director, Manager, or Representative (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of Ordinary Shares |
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
| Volume | 460 shares |
| Price per Share | £15.7498 |
| Transaction Date | April 19, 2017 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single transaction involving the re-investment of dividends paid to shareholders on April 13, 2017.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transaction was executed by Dr. S. Dexter, identified as a PCA of Dr. P. J. T. Vallance (President, R&D).
Key Facts for Investor Verification
- The transaction represents an acquisition of 460 ordinary shares via dividend re-investment.
- The transaction price was £15.7498 per share.
- The transaction occurred on April 19, 2017, on the London Stock Exchange.
- The filing does not contain financial results or strategic updates for the company.